Collection of Vaginal Microbiota Samples (VAGINOTYPE) (VAGINOTYPE)

Collection of Vaginal Microbiota from Healthy Women Subject to Vaginal and Urinary Infections (VAGINOTYPE)

The aim of this study is to collect vaginal microbiota samples from healthy women who are subject to vaginal and urinary infections.

Study Overview

• Status: Completed
• Conditions: Vaginal Microbiota

Detailed Description

The goal of this study is to collect vaginal swab samples in order to gain knowledge on vaginal microbial communities of healthy women who have had experiences with vaginal and urinary infections.

Eligible participants will be enrolled in the study for a total duration of 1 day, where they will provide consent, answer a questionnaire and collect the vaginal samples.

• Study Type: Observational
• Enrollment (Actual): 200

Contacts and Locations

Study Locations

• France
  • Paris, France, 75012
    • Biofortis, Unité d'Investigation Clinique
  • Saint-Herblain, France, 44800
    • Biofortis, Unité d'Investigation Clinique

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Healthy females from 18 to 60 years of age inclusively that are willing to participate in the study and to provide a vaginal swab sample. Females that are subject to vaginal or urinary infections.

Description

Inclusion Criteria:

I1. Age between 18 and 60 years (limits included),

I2. BMI between 18 and 30 kg/m² (limits included),

I3. Good general and mental health within the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination,

I4. Able and willing to participate to the study by complying with the protocol procedures as evidenced by the dated and signed informed consent form,

I5. Affiliated with a social security scheme,

I6. Women who have had a vaginal or urinary infection in the last two years.

Exclusion Criteria:

E1. Suffering from gastrointestinal acute or chronic disease or complication (e.g. celiac disease, gastroesophageal reflux disease, gastric or duodenal ulcer, Crohn's disease, hemorrhoids, irritable bowel syndrome) or frequent gastrointestinal disorders (e.g. diarrhea, nausea, vomiting, abdominal pain, constipation, hemorrhoids...)

E2. Any infectious gastrointestinal complaint within 4 weeks before V1

E3. Suffering from a metabolic disorder such as diabetes, thyroidal trouble, arterial hypertension or other metabolic disorder or any disease requiring a chronic treatment

E4. Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, cardiac, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or disease found to be inconsistent with the conduct of the study by the investigator

E5. Suffering from a pathology of the oral sphere (untreated caries, gingivitis, periodontitis, abscess, etc.) or having a positive result in an oral swab test for STIs (chlamydia, gonococcus, syphilis, herpes, etc.)

E6. Women affected by a Sexually Transmitted Infection (STI) or Disease (STD) such as HPV (Human PapillomaVirus), Chlamydia infection, syphilis, gonorrhea, genital herpes

E7. Having undergone a surgical procedure likely to disrupt the gut microbiome within the 6 months prior to the V1 visit, especially bariatric surgery

E8. Coloscopy within 3 months prior to the visit

E9. Women who gave birth within one year of the visit, women who are pregnant or intend to become pregnant during the study, women who are breastfeeding

E10.Previous or current antibiotic, antiviral, antifungal, proton pump inhibitor, or any treatment which may disrupt the microbiota in the 4 weeks prior to the V1 visit

E11.In the process of quitting smoking or having started smoking less than 6 months ago

E12.Taking part in another clinical trial or being in the exclusion period of a previous clinical trial

E13. Having received, during the last 12 months, indemnities for clinical trial higher or equal to 6000 Euros

E14.Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision

E15.Presenting a psychological or linguistic incapability to sign the informed consent

E16.Impossible to contact in case of emergency

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composition of the vaginal microbiome	Vaginal microbiota composition (α-diversity, β-diversity, and relative abundance at the genus and species level) at a single point in time via shotgun sequencing.	1 day

Collaborators and Investigators

• Sponsor: Lallemand Health Solutions
• Collaborators: BioFortis
• Investigators: Principal Investigator: Isabelle Metreau, MD, Biofortis, Unité d'Investigation Clinique de Saint-Herblain

Study record dates

Study Major Dates

• Study Start (Actual): May 14, 2024
• Primary Completion (Actual): September 11, 2024
• Study Completion (Actual): September 11, 2024

Study Registration Dates

• First Submitted: June 27, 2024
• First Submitted That Met QC Criteria: June 27, 2024
• First Posted (Actual): July 3, 2024

Study Record Updates

• Last Update Posted (Actual): September 19, 2024
• Last Update Submitted That Met QC Criteria: September 17, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: Urinary tract infections; Women's health; Vaginal infections; VAGINOTYPE
• Other Study ID Numbers: L-031; 2022-A01997-36 (Other Identifier: ID-RCB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No